Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 14/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1813726 | 0.94 | ADAMTS5 (0.88) | ADAMTS5MEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL1812427 | 0.91 | ADAMTS5 (0.81) | ADAMTS5MEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL1815205 | 0.89 | ADAMTS5 (0.79) | ADAMTS5MEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL1813036 | 0.88 | ADAMTS5 (1.00) | ADAMTS5HSP90AA1NPC1RAB9AKDM4E | |
| SCHEMBL27778697 | 0.87 | ADAMTS5 (0.82) | ADAMTS5HSP90AA1NPC1RAB9AKDM4E | |
| SCHEMBL1812475 | 0.86 | ADAMTS5 (0.73) | ADAMTS5MEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL1814802 | 0.86 | ADAMTS5 (1.00) | ADAMTS5HSP90AA1NPC1RAB9AKDM4E | |
| SCHEMBL1815938 | 0.85 | ADAMTS5 (1.00) | ADAMTS5MEN1KMT2AHSP90AA1RAB9A | |
| SCHEMBL1814720 | 0.84 | ADAMTS5 (0.71) | ADAMTS5MEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL1814541 | 0.84 | ADAMTS5 (0.78) | ADAMTS5MEN1HTTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | claimed |
| CN-101505751-A | 8-hydroxyquinoline compounds and methods thereof | WYETH CORP (US) | 2009-08-12 | — | — | CN | claimed |
| EP-2056823-A2 | 8-HYDROXYQUINOLINE COMPOUNDS AND METHODS THEREOF | Wyeth (US) | 2009-05-13 | — | — | EP | claimed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | claimed |
| WO-2008024922-A2 | 8-HYDROXYQUINOLINE COMPOUNDS AND METHODS THEREOF | WYETH (US) | 2008-02-28 | — | — | WO | claimed |
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | disclosed |
| CN-101505751-A | 8-hydroxyquinoline compounds and methods thereof | WYETH CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-2056823-A2 | 8-HYDROXYQUINOLINE COMPOUNDS AND METHODS THEREOF | Wyeth (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008024922-A2 | 8-HYDROXYQUINOLINE COMPOUNDS AND METHODS THEREOF | WYETH (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | ADAMTS5 11/4885MEN1 2254/4885HTT 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.